Causes of pulmonary hypertension in sarcoidosis patients
| Condition | Potential treatments |
| Vascular disease | |
| Vasculitis | Glucocorticoids and other anti-inflammatory treatments Pulmonary vasodilators |
| Granulomatous vascular involvement | Glucocorticoids and other anti-inflammatory treatments Pulmonary vasodilators |
| Veno-occlusive disease | Glucocorticoids and other anti-inflammatory treatments Careful use of pulmonary vasodilators |
| Pulmonary embolism (CTEPH) | Anticoagulation Balloon pulmonary angioplasty Pulmonary endarterectomy Pulmonary vasodilators |
| Interstitial lung disease | |
| Parenchymal lung disease due to granulomas | Glucocorticoids and other anti-inflammatory treatments |
| Parenchymal lung disease due to fibrosis | Anti-fibrotic agents |
| Hilar and mediastinal distortion | |
| Pulmonary artery/vein extrinsic compression | Glucocorticoids and other anti-inflammatory treatments Dilation and/or stenting of compressed vessels |
| Fibrosing mediastinitis | Dilation and/or stenting of compressed vessels |
| Extrapulmonary disease | |
| Left ventricular systolic dysfunction | Glucocorticoids and other anti-inflammatory treatments Diuretics, afterload reduction |
| Left ventricular diastolic dysfunction | Diuretics |
| Sleep apnoea | CPAP, oxygen and other measures |
| Liver disease | Glucocorticoids and other anti-inflammatory treatments |
CTEPH: chronic thromboembolic pulmonary hypertension; CPAP: continuous positive airway pressure.